Merck KGaA Acquires Rights to PI-2301 Program for Multiple Sclerosis
Advertisement
Merck announced that it has acquired worldwide exclusive rights to PI-2301, an experimental drug for multiple sclerosis, previously developed by Peptimmune Inc. PI-2301 has completed Phase 1b in multiple sclerosis and is ready to initiate phase 2 clinical trials.
“Over the years we have continuously worked on developing innovative treatment options that meet the individual needs of people living with multiple sclerosis,” said Susan Herbert, Head of Global Portfolio Development at the Merck Serono division. “We are pleased to strengthen our development pipeline with the PI-2301 compound, which could play a valuable role in the treatment of this debilitating disease.”
The acquisition of PI-2301 covers its worldwide exclusive development and commercialization rights.
PI-2301 is a second-generation peptide copolymer that is thought to enhance the regulatory response of the immune system. Merck will investigate the application of this product in autoimmune diseases such as multiple sclerosis.
Most read news
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
Last viewed contents

Genetics and intestinal microbiome determine susceptibility to multiple sclerosis - Study shows the link between genetics, intestinal microbiome and multiple sclerosis in mice for the first time
GATC Biotech Opens Third Sequencing Laboratory in Europe - Facilities will be situated in Düsseldorf, Germany
Bayer focuses resources on growth and innovation - Planned net reduction of about 2,000 jobs worldwide by the end of 2012
